In view of the plans made by national health authorities in every country across the world for the widespread vaccination of individuals against the SARS-CoV-2 virus, the Thalassaemia International Federation herein presents the latest information concerning the to-date authorized vaccinations, as well as the Federation’s position about the vaccination of patients with haemoglobin disorders against SARS-CoV-2.
FDA grants Orphan Drug Designation for ARU-1801 for the Treatment of Sickle Cell Disease & β-thalassaemia
janvier 27, 2020
juin 19, 2020
septembre 5, 2019
Coronavirus Disease among Persons with Sickle Cell Diseasejuillet 13, 2020